Methods for treating combined radiation and thermal injury
US-9272013-B2 · Mar 1, 2016 · US
Methods for treating multiple sclerosis
US9623084B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9623084-B2 |
| Application number | US-201414769363-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 13, 2014 |
| Priority date | Mar 15, 2013 |
| Publication date | Apr 18, 2017 |
| Grant date | Apr 18, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides methods for treating or limiting development of multiple sclerosis by administering angiotensin peptides to a subject with multiple sclerosis or at risk of developing multiple sclerosis.
First claim
Opening claim text (preview).
We claim: 1. A method for limiting demyelination and/or promoting remyelination, comprising administering to a subject in need thereof an amount effective of a peptide comprising A(1-7), (Asp-Arg-Val-Tyr-Ile-His-Pro; (SEQ ID NO: 4), or salt thereof to limit demyelination and/or promote remyelination in the subject. 2. The method of claim 1 , wherein the method is for limiting demyelination. 3. The method of claim 1 , wherein the method is for promoting remyelination. 4. The method of claim 1 , wherein the peptide is administered in a polymer formulation. 5. The method of claim 4 , wherein the polymer formulation comprises a Poly-D,L-Lactic-Co-Glycolic Acid (PLGA) polymer, a poly-lactic acid (PLA), and co-polymers thereof, polycaprolactone particles, and chitosan nanoparticles. 6. The method of claim 4 , wherein the method is for limiting demyelination. 7. The method of claim 4 , wherein the method is for promoting remyelination. 8. The method of claim 5 , wherein the method is for limiting demyelination. 9. The method of claim 5 , wherein the method is for promoting remyelination.
Assignees
Inventors
Classifications
- A61K38/22Primary
Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35) · CPC title
Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9623084B2 cover?
- The present invention provides methods for treating or limiting development of multiple sclerosis by administering angiotensin peptides to a subject with multiple sclerosis or at risk of developing multiple sclerosis.
- Who is the assignee on this patent?
- Univ Southern California
- What technology area does this patent fall under?
- Primary CPC classification A61K38/22. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).